Format

Send to

Choose Destination
Int J Mycobacteriol. 2018 Jan-Mar;7(1):89-91. doi: 10.4103/ijmy.ijmy_161_17.

Uric acid levels in patients on antituberculosis drugs in the southwest Region of Cameroon.

Author information

1
Department of Medical Laboratory Science, Faculty of Health Sciences, University of Buea, Buea, Cameroon; Bacteriology Department, Noguchi Memorial Institute for Medical Research, University of Ghana, Legon, Accra, Ghana.
2
Department of Medical Laboratory Science, Faculty of Health Sciences, University of Buea, Buea, ; Laboratory of Endocrinology and Radioelements (LERE), Medical Research Centre (CRM), Institute of Medical Research and Studies on Medicinal Plants (IMPM), Yaounde-, Cameroon.
3
Department of Medical Laboratory Science, College of Medical Sciences, University of Calabar, Calabar, Nigeria.
4
Department of Medical Laboratory Science, Faculty of Health Sciences and Technology, Ebonyi State University, Abakaliki, Nigeria.
5
Department of Public Health and Hygiene, Faculty of Health Sciences, University of Buea, Buea, Cameroon.

Abstract

Background:

Antituberculosis drugs (ATDs) efficiently combat Mycobacterium tuberculosis either through direct molecular interactions or those of its metabolites. However, a variety of adverse effects have been reported, leading to frequent interruptions of treatment. To investigate the possible metabolic disturbances resulting from antituberculosis (TB) treatment, the uric acid (UA) level of patients on ATDs was measured in the southwest region of Cameroon.

Methods:

This hospital-based cross-sectional study involved 96 TB patients on ATDs and 32 controls who were neither on ATDs nor any other treatment that could increase UA levels. The hospital records of consenting participants were reviewed for medical history and questionnaires were issued. About 2 ml venous blood was collected and analyzed using spectrophotometers to determine UA levels.

Results:

Hyperuricemia was observed in 56/96 (58.3%) of the studied group as compared with 4/32 (12.5%) in the control group (P < 0.001). Our results indicated that treatment duration was significantly associated with hyperuricemia (P = 0.0016) while gender (P = 0.1275) was not.

Conclusion:

Hyperuricemia is associated with ATDs, with treatment duration being a significant factor. The disorder should be closely monitored, especially during the intensive phase of treatment.

KEYWORDS:

Antituberculosis drugs; Cameroon; hyperuricemia; intensive phase; southwest region

PMID:
29516892
DOI:
10.4103/ijmy.ijmy_161_17
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Medknow Publications and Media Pvt Ltd
Loading ...
Support Center